QuickView: Initial proof-of-concept established
AEM-28 has demonstrated significant reductions in both VLDL and triglycerides in the Phase I/II programme. This reinforces prior lipid biomarker trends observed in healthy volunteers. These data provide initial proof-of-concept for AEM-28, and more broadly for follow-on products within Capstone’s Apo-E mimetic pipeline including AEM-28-02, supporting progression into further trials, although additional funding will be needed. Future development could include an orphan indication, requiring only small trials for approval, in addition to potential in major CV disorders.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.